Current Trends in the Treatment of Dupuytren Disease in Spain

Abstract

Objective Assessment of the treatment trends of Spanish surgeons in clinical practice by making clinical assumptions in Dupuytren's disease (DD).

Material and Method A survey was sent to the members of the Spanish Society for Surgery of the Hand (Sociedad Española de Cirugía de la Mano, SECMA) posing primary and secondary clinical cases. A relationship is established between the selected treatment, the characteristics of the participating surgeons, and the characteristics of the primary clinical cases. Treatment preferences in recurrences are assessed descriptively.

Results In total, 127 surveys were answered. 62.2% of the participants had experience with the use of collagenase and were the basis of the analysis. In primary cases, surgeons with more practice time tended to choose collagenase as treatment for DD. Surgeons who reported higher frequency of collagenase use (67.4% vs. 25.7%) were up to 6 times more likely to indicate such treatment. The patient's age under 50 years was the variable with the greatest association strength for the choice of collagenase treatment (OR = 3.8; CI95% 1.9–7.6). In recurrences, among all clinical cases, the most common answer given by the surgeons was partial fasciectomy.

Conclusions Partial fasciectomy continues to be the most widely used treatment for DD in Spain. In primary cases, collagenase is an alternative adopted by experienced surgeons, and in treatments for young patients. In recurrences, partial fasciectomy is the preferred technique.

Keywords

dupuytren disease - faciectomy - collagenase - survey - treatment

• References

• 1 Muñoz-Peñin R, Lwoff N, Renú JMA. Enfermedad de Dupuytren, una vista panorámica de nuestro entorno. Rev Iberoam Cir Mano 2011; 39 (02) 126-134
• 2 McMillan C, Yeung C, Binhammer P. Variation in treatment recommendations for Dupuytren disease. J Hand Surg Am 2017; 42 (12) 963-970.e6
• 3 Hueston JT. Dupuytren's contracture: The trend to conservatism. Ann R Coll Surg Engl 1965; 36 (03) 134-151
• 4 Hurst LC, Badalamente MA, Hentz VR. , et al; CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009; 361 (10) 968-979
• 5 Engstrand C, Krevers B, Kvist J. Interrater reliability in finger joint goniometer measurement in Dupuytren's disease. Am J Occup Ther 2012; 66 (01) 98-103
• 6 Broekstra DC, Lanting R, Werker PMN, van den Heuvel ER. Intra- and inter-observer agreement on diagnosis of Dupuytren disease, measurements of severity of contracture, and disease extent. Man Ther 2015; 20 (04) 580-586
• 7 Ellis B, Bruton A. A study to compare the reliability of composite finger flexion with goniometry for measurement of range of motion in the hand. Clin Rehabil 2002; 16 (05) 562-570
• 8 Felici N, Marcoccio I, Giunta R. , et al. Dupuytren contracture recurrence project: reaching consensus on a definition of recurrence. Handchir Mikrochir Plast Chir 2014; 46 (06) 350-354
• 9 Clarkson P. The radical fasciectomy operation for Dupuytren's disease: a condemnation. Br J Plast Surg 1963; 16: 273-279
• 10 Hakstian RW. Long-term results of extensive fasciectomy. Br J Plast Surg 1966; 19 (02) 140-149
• 11 Hueston JT. Limited fasciectomy for Dupuytren's contracture. Plast Reconstr Surg Transplant Bull 1961; 27 (06) 569-585
• 12 McGrouther DA. La maladie de Dupuytren. To incise or excise?. J Hand Surg [Br] 1988; 13 (04) 368-370
• 13 Lipman MD, Carstensen SE, Deal DN. Trends in the treatment of Dupuytren disease in the United States between 2007 and 2014. Hand (N Y) 2017; 12 (01) 13-20
• 14 Thayer MK, Somerson JS, Huang JI. Changes in provider treatment patterns for Dupuytren's contracture: Analysis of trends in Medicare beneficiaries. Plast Reconstr Surg Glob Open 2018; 6 (10) e1932
• 15 Carr L, Michelotti B, Brgoch M, Hauck R, Ingraham J. Dupuytren disease management trends: A Survey of Hand Surgeons. Hand (N Y) 2020; 15 (01) 97-102
• 16 Marks M, Krefter C, Herren DB. Treatment methods for patients with Dupuytren's disease in Switzerland. Handchir Mikrochir Plast Chir Organ Deutschsprachigen Arbeitsgemeinschaft Handchir Organ Deutschsprachigen Arbeitsgemeinschaft Mikrochir Peripher Nerven Gefasse Organ V 2016; 48 (03) 155-160
• 17 Leskelä R-L, Herse F, Torkki P, Laine J, Vilkuna T, Raatikainen T. Analysis of the adoption of new health technology: the case of Dupuytren's disease. Int J Healthc Technol Manag 2016; 15 (03) 210-227
• 18 Pajardi G, Parolo C, Willbrand S, Hurst L, Grablutz LB. American and european regulations. In: Collagenase in Dupuytren disease. Springer; Cham: 2018: 119-130
• 19 Au-Yong ITH, Wildin CJ, Dias JJ, Page RE. A review of common practice in Dupuytren surgery. Tech Hand Up Extrem Surg 2005; 9 (04) 178-187
• 20 Beaudreuil J, Allard A, Zerkak D. , et al; URAM Study Group. Unité Rhumatologique des Affections de la Main (URAM) scale: development and validation of a tool to assess Dupuytren's disease-specific disability. Arthritis Care Res (Hoboken) 2011; 63 (10) 1448-1455
• 21 Engstrand C, Kvist J, Krevers B. Patients' perspective on surgical intervention for Dupuytren's disease - experiences, expectations and appraisal of results. Disabil Rehabil 2016; 38 (26) 2538-2549
• 22 Eppler SL, Kakar S, Sheikholeslami N, Sun B, Pennell H, Kamal RN. Defining Quality in Hand Surgery From the Patient's Perspective: A Qualitative Analysis. J Hand Surg Am 2019; 44 (04) 311-320.e4
• 23 Poelstra R, Selles RW, Slijper HP. , et al; Hand-Wrist Study Group. Better patients' treatment experiences are associated with better postoperative results in Dupuytren's disease. J Hand Surg Eur Vol 2018; 43 (08) 848-854
• 24 Ball C, Pratt AL, Nanchahal J. Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice. BMC Musculoskelet Disord 2013; 14: 131